Home Collaborators

Collaborators

Working with healthcare professionals is vital to the development of new diagnostics. They provide us with valuable, independent and expert knowledge derived from their clinical and management experience.

GynEC®-DX was developed in collaboration with Vall d’Hebron hospital (Barcelona) and validated in a double blind, prospective, multicenter study involving 14 Spanish hospitals:

Biomarkers-guided surveillance of patients with Lynch syndrome

Since 2015 La Paz University hospital (Madrid) has been leading a phase IV clinical study to evaluate the of GynEC®-DX in the biomarkers-guided surveillance of patients with Lynch syndrome. Preliminary results of this project, led by Drs. Javier de Santiago García and María Dolores Diestro Tejeda, have been presented at 33rd National Congress of the Gynecologic Oncology Section of the Spanish Society of Gynecology and Obstetrics (SEGO).

Estudio en fase IV del test de diagnóstico molecular de cáncer de endometrio GynEC®-DX sobre muestras insuficientes o no concluyentes

Since 2015 La Paz University hospital (Madrid) has been leading a phase IV clinical study to evaluate the of GynEC®-DX in the biomarkers-guided surveillance of patients with Lynch syndrome. Preliminary results of this project, led by Drs. Javier de Santiago García and María Dolores Diestro Tejeda, have been presented at 33rd National Congress of the Gynecologic Oncology Section of the Spanish Society of Gynecology and Obstetrics (SEGO).

Estudio en fase IV del test de diagnóstico molecular de cáncer de endometrio GynEC®-DX sobre muestras insuficientes o no concluyentes

A multicenter study  involving Jiménez Díaz Fundation (Madrid), Dexeus fundation (Barcelona), and the hospitals of Ntra Sra. de Candelaría (Tenerife), Henares (Madrid), Infanta Elena (Madrid) and Álvarez Buylla (Oviedo) has tested the capacity of GynEC®-DX to exploit endometrial aspirates from patients that had an inconclusive result in Anatomical Pathology.

The project, coordinated by Drs Francisco Javier Plaza Arranz and Raquel Sanz Baro, concluded that GynEC®-DX yields a conclusive result in 88.9% of the samples in which the pathologist could not obtain a diagnosis through histological analysis (Sanz, 2016). 

Reference: Sanz Baro (2016) Estudio en fase IV del test de diagnóstico molecular de cáncer de endometrio GynEC®-DX sobre muestras insuficientes o no concluyentes. Doctoral thesis, Autonomous University of Madrid.

Clínica Pedrosa (Granada) provided us with their clinical and management experience with GynEC®-DX in the context of a private clinic. The purpose of this retrospective observational study was to evaluate how gynaecologists weigh different clinical factors (eg, relative importance) in their decision to use the test, what was the moment of use of GynEC®-DX and its outcome in the diagnostic algorithm. Results were presented in the 5th GINEP Scientific Meeting for private gynaecologists (Palma de Mallorca, Oct. 2016).

Reig Jofre participates with Ability Pharmaceuticals (project leader), Atrys Health, Laboratorio ODX, Fundació Hospital Universitari Vall d’Hebron, Institut de Recerca Biomedica de Lleida and Fundació privada Dr. Pifarre in the PredictGyn project funded by the European Regional Development Fund in collaboration with the Spanish Ministry of Economy and Competitiveness.

This project has for objective the development of new markers for diagnosis and prediction in gynecological cancers.

Our specific objective is to develop a biomarker-based prognosis algorithm complementary to GynEC®-DX.

GynEC®-DX es una licencia de Laboratorio Reig Jofre, S.A. 2017 Todos los derechos reservados